SCHEDULE: 3i LP Boosts CNBX Pharma Stake to 9.9%

3i, LP and its affiliates have updated their beneficial ownership in CNBX Pharmaceuticals Inc. to 9.9% of outstanding common stock, totaling 13,573,116 shares.

Summary

• 3i, LP, 3i Management LLC, and Maier Joshua Tarlow collectively report beneficial ownership of 13,573,116 shares of CNBX Pharmaceuticals Inc. common stock.
• This represents 9.9% of the 134,511,352 shares outstanding as of June 30, 2025.
• The ownership consists of 12,217,438 directly held common shares and 1,355,678 shares convertible from a senior secured convertible note.
• The convertible note has a principal amount of approximately $752,255.
• Conversion of the note is subject to a 9.99% beneficial ownership limitation, preventing ownership from exceeding this threshold.
• The reporting persons share voting and dispositive power over all beneficially owned shares.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and typically carries a neutral sentiment. It indicates a significant, but not controlling, stake by an institutional investor.

Risks

• The conversion of the senior secured convertible note is subject to a 9.99% beneficial ownership limitation, which restricts 3i, LP from converting if it would result in ownership exceeding this threshold.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This Schedule 13G filing reflects a significant institutional investment in CNBX Pharmaceuticals Inc., a company operating in the pharmaceutical sector. Such filings are routine disclosures of substantial ownership stakes and do not inherently indicate broader industry trends, though they can signal investor confidence or strategic positioning within the sector.

Comparison to Industry Standards

• This filing is a standard beneficial ownership disclosure (Schedule 13G) and does not contain performance metrics or operational results that would allow for a direct comparison to industry standards or specific comparable companies/projects. It solely reports the ownership stake of a specific investor group.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence or a long-term interest in the company.

Next Steps

• The reporting persons have agreed to file all subsequent amendments to this Schedule 13G jointly.

Key Dates

Recommendation

This filing is a routine disclosure of beneficial ownership and does not provide sufficient information on the company's financial performance, strategic direction, or market valuation to warrant a 'buy' or 'sell' recommendation. The continued significant stake by 3i, LP suggests a sustained interest, supporting a 'hold' position for existing investors, while new investors would require more comprehensive company analysis.

Keywords

CNBX Pharmaceuticals, 3i LP, Beneficial Ownership, Schedule 13G, Common Stock, Convertible Note, Institutional Investor, SEC Filing, Shareholder Update